Isomorphic Labs have announced that it has entered into a strategic research collaboration with Eli Lilly and Company and a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
Signal detection in post-market drug monitoring has changed little in 70 years, but now that shake-up is coming in the form of advanced AI technology combined with democratised access to standardised real-world data, Elizabeth Smalley explores.
Josh Ludwig, Global Commercial Director, ScaleReady explores the necessity of simplifying cell and gene therapy in order to successfully integrate artificial intelligence and automation technologies in our latest EPM insight.
Timothy Korwan, Director of Technical Applications; Alex Joyner, Digital Lab Product Manager; and Sarah Ann Landry, Operations Manager, Fluid Handling Solutions, at Avantor discuss leveraging AI for inventory management of single-use solutions.
Julie Neal, Director at management consultancy, Vendigital, and Dr. Ulli Waltinger, Vice President specialising in AI and IoT at Siemens Advanta explore Life Sciences: A Data-Led Approach to Sustainability Transformation.
The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally. AI could give us the edge over the next global health threat, says Jeremy Skillington, PhD, CEO of Poolbeg Pharma.
In this article, we will unravel the mysteries of Materiovigilance and dive into how it plays a crucial role in the safety of SaMD. We'll explore the challenges, the strategies, and even how modern tools like Artificial Intelligence are changing.
Helping to make pharmaceutical manufacturing compliant, safer, and faster, tech startup Leucine is today announcing a $7M series A funding round led by Ecolab Inc., a strategic investor, to scale its Compliance Cloud platform globally.
Jerry Temko, Managing Director, In-House Counsel Group, Major, Lindsey & Africa explores how Life science companies are becoming more alive to the role that in-house legal teams will play in safely and successfully taking on the AI challenge.
Charles Collins-Chase, partner, and Harry Muttock, associate, at international IP law firm, Finnegan, explore AI’s potential and how companies can use IP to protect their investments in AI technology.
